This site is intended for healthcare professionals
Drug news

Results from study of Inspire Upper Airway Stimulation (UAS) System in obstructive sleep apnea published in Otolaryngol Head Neck Surg journal- Inspire Medical Systems

Read time: 1 mins
Last updated:21st Nov 2015
Published:21st Nov 2015
Source: Pharmawand

Inspire Medical Systems has announced the results of a landmark long-term clinical study for its Inspire Upper Airway Stimulation (UAS) System, the first FDA-approved implantable neurostimulation treatment for people diagnosed with Obstructive Sleep Apnea (OSA). The Stimulation Therapy for Apnea Reduction (STAR) trial was conducted at 22 leading sleep medicine centers across the United States and Europe. One-year STAR trial outcome measures, published in the New England Journal of Medicine in 2014, showed that sleep apnea patients receiving Inspire therapy experienced significant reductions in sleep apnea events and significant improvements in quality of life measures. The new long-term study outcomes showed that the improvements observed at one-year were sustained at the three-year follow up mark.

The outcomes include a 78 percent reduction in apnea-hypopnea index (AHI) from baseline, an 80 percent reduction in oxygen desaturation events from baseline, an 80 percent of bed partners reported soft or no snoring as compared to 17 percent of bed partners at baseline and Quality of life measures, including daytime sleepiness and functioning, showed clinically meaningful improvements and a return to normal levels over baseline. The results were published in the online issue of Otolaryngology – Head and Neck Surgery.

See:  Three-Year Outcomes of Cranial Nerve Stimulation for Obstructive Sleep Apnea - The STAR Trial

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.